Product image of ATRA-POWER 25mg/2.5ml (Atracurium Besylate) 25mg/2.5ml supplied by GNH India

ATRA-POWER 25mg/2.5ml

Active Ingredient:
Atracurium Besylate
Origin:
India

ATRA-POWER 25mg/2.5ml (Atracurium Besylate) 25mg/2.5ml

Atracurium Besylate, the active ingredient in ATRA-POWER 25mg/2.5ml, is a non‑depolarizing neuromuscular blocking agent presented as a 25 mg/2.5 ml injection solution for intravenous use. It facilitates endotracheal intubation and provides skeletal muscle relaxation during surgery and mechanical ventilation.

GNH India supplies ATRA-POWER 25mg/2.5ml as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Strength

25mg/2.5ml

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Atracurium Besylate is a non‑depolarizing neuromuscular blocker used in peri‑operative and critical‑care settings.

  • Facilitation of endotracheal intubation: provides rapid muscle relaxation to allow safe airway placement.
  • Muscle relaxation during surgery: maintains skeletal muscle paralysis throughout general anesthesia.
  • Adjunct for mechanical ventilation: enables controlled ventilation by preventing spontaneous breathing efforts.

How It Works

  • Atracurium Besylate acts as a competitive antagonist at nicotinic acetylcholine receptors on the motor end‑plate of skeletal muscle. By binding these receptors it blocks acetylcholine‑mediated depolarization, preventing muscle fiber contraction and producing dose‑dependent skeletal muscle relaxation without depolarizing the membrane.

Side Effects

Atracurium Besylate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Flushing: transient redness of the skin.
  • Tachycardia: increased heart rate.
  • Hypotension: lowered blood pressure.
  • Bronchospasm: narrowing of the airways.
  • Increased salivation: excess oral secretions.
  • Skin rash: mild dermatologic irritation.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate intervention.
  • Prolonged paralysis: extended muscle weakness beyond the intended period.
  • Malignant hyperthermia‑like reaction: rare hypermetabolic crisis.
  • Severe hypotension: marked drop in blood pressure.
  • Myocardial depression: reduced cardiac contractility.
  • Respiratory arrest: cessation of breathing requiring ventilation support.

Precautions & Warnings

When using Atracurium Besylate, clinicians should observe several safety measures.

  • Assess neuromuscular function: monitor train‑of‑four ratio during infusion.
  • Avoid use in patients with known hypersensitivity to atracurium or related compounds.
  • Use with caution in patients with cardiovascular instability: monitor blood pressure and heart rate.
  • Adjust dose in patients with hepatic or renal impairment: slower metabolism may prolong effect.
  • Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Atracurium Besylate can interact with other drugs, influencing the depth and duration of neuromuscular blockade.

Major Interactions (Avoid)

  • Concurrent use of aminoglycoside antibiotics: may potentiate neuromuscular blockade.
  • Combination with other non‑depolarizing muscle relaxants: additive paralysis risk.
  • Use with potent inhalational anesthetics (e.g., halothane): can enhance block.

Moderate Interactions (Monitor Closely)

  • Interaction with magnesium sulfate: may increase block duration.
  • Co‑administration with calcium channel blockers: may augment hypotensive effect.
  • Concurrent use of cholinesterase inhibitors (e.g., neostigmine) for reversal: may require dose adjustment.

Frequently Asked Questions

ATRA-POWER contains atracurium besylate, a neuromuscular blocking agent used to facilitate endotracheal intubation, provide skeletal muscle relaxation during surgical procedures, and act as an adjunct to control breathing in patients receiving mechanical ventilation.

Atracurium besylate competitively blocks nicotinic acetylcholine receptors at the motor end‑plate, preventing acetylcholine from triggering depolarization. This inhibition stops muscle contraction, producing dose‑dependent skeletal muscle relaxation without causing a depolarizing phase.

The dose of ATRA-POWER is individualized by the prescribing clinician based on the patient’s weight, clinical condition, and the required depth of muscle relaxation. Dosing regimens are established in the peri‑operative or intensive‑care setting and are not standardized in public literature.

Atracurium besylate is classified as pregnancy category unknown. It should be used only when the potential benefit justifies any potential risk to the fetus. Limited data exist for breastfeeding, so the drug should be administered with caution and only if essential.

To order ATRA-POWER, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Atracurium is an intermediate‑acting, non‑depolarizing blocker that undergoes Hofmann elimination, making its metabolism independent of renal or hepatic function. Compared with agents like rocuronium or vecuronium, atracurium has a shorter duration and does not rely on organ clearance, which can be advantageous in patients with organ impairment.

ATRA-POWER should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if the container is damaged or the solution appears discolored.

ATRA-POWER is supplied as a sterile injection solution for intravenous use. It is typically given as a rapid bolus for intubation or as a continuous infusion to maintain muscle relaxation during surgery or mechanical ventilation, under continuous neuromuscular monitoring.

Serious risks include anaphylactic reactions, prolonged or unexpected paralysis, malignant hyperthermia‑like events, severe hypotension, myocardial depression, and respiratory arrest. Immediate recognition and supportive measures, such as airway management and cardiovascular support, are essential.

Patients with a known hypersensitivity to atracurium, other bis‑benzyl quaternary ammonium compounds, or any component of the formulation should not receive ATRA-POWER. Caution is also advised in individuals with severe cardiovascular instability or uncontrolled asthma.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Atracurium Besylate

Tracrium 25mg/2.5ml

Tracrium 25mg/2.5ml

25mg/2.5ml Tablet
Atrapure 5ml

Atrapure 5ml

50mg/5ml Ampoules
Atacurium 5ml

Atacurium 5ml

10mg/ml x 5ml Ampoules
Quanir 50mg/5ml

Quanir 50mg/5ml

50mg/5ml Ampoules

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT